Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and Co-Founder Gareth Sheridan will present as part of the CEO Spotlight event at the 2026 Georgia Life Sciences Summit. The summit, scheduled for Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, will bring together leaders across biotechnology, medical technology, research, manufacturing and investment sectors.
The presentation is expected to highlight Nutriband's lead product under development: an abuse-deterrent fentanyl patch incorporating the company's AVERSA™ technology. This technology is designed to incorporate aversive agents into transdermal patches to help prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential. The announcement comes at a time when the opioid crisis continues to pose significant public health challenges, making abuse-deterrent formulations a critical area of innovation.
According to the company, AVERSA™ technology can be incorporated into any transdermal patch, offering a versatile solution to a widespread problem. The technology aims to reduce the risk of tampering and unintended use, which is particularly relevant for potent opioids like fentanyl. By presenting at the summit, Nutriband seeks to engage with industry peers and potential partners, potentially accelerating the development and commercialization of its technology.
The Georgia Life Sciences Summit is a key event for the life sciences community, providing a platform for networking, knowledge exchange, and showcasing cutting-edge developments. Nutriband's participation underscores its commitment to addressing the opioid epidemic through innovative pharmaceutical solutions. The company's focus on abuse-deterrent technologies aligns with broader regulatory and societal efforts to curb prescription drug abuse.
Investors and industry observers will be watching closely, as the presentation could provide insights into Nutriband's strategic direction and the potential market impact of AVERSA™. The company's progress in this area may also influence future regulatory approvals and partnerships, given the increasing emphasis on abuse-deterrent formulations in pain management.
For more information about Nutriband and its pipeline, visit the company's website at www.nutriband.com. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
